Risk prediction: Increasingly important, but questions still remain Andrew M. Tonkin Invited Commentary Pages: 1 - 2
The challenges of conducting clinical endpoint studies Jonathan L. IsaacsohnTiffany A. KhodadadJeffrey D. Vest OriginalPaper Pages: 11 - 14
Efficacy of over-the-counter nutritional supplements Michael H. DavidsonChris T. Geohas OriginalPaper Pages: 15 - 21
The development of combination drugs for atherosclerosis Donald M. Black OriginalPaper Pages: 29 - 32
Vascular pleiotropy of statins: Clinical evidence and biochemical mechanisms A. S. Callahan III OriginalPaper Pages: 33 - 37
Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor? Sean RulandPhilip B. Gorelick OriginalPaper Pages: 38 - 43
Early use of statins in acute coronary syndromes Joshua M. SpinRandall H. Vagelos OriginalPaper Pages: 44 - 51
What is the cardioprotective role of hormone replacement therapy? Howard N. HodisWendy J. MackRoger Lobo OriginalPaper Pages: 56 - 66
Cardiovascular and medical ramifications of treatment of subclinical hypothyroidism Charles J. GlueckPatricia Streicher OriginalPaper Pages: 73 - 77
Naturally available oils contain phytosterols that affect cholesterol absorption Daniel Eisenberg Clinical trials report Pages: 78 - 78
